Curated News
By: NewsRamp Editorial Staff
May 21, 2025
Telomir Pharmaceuticals Receives $3M Investment, Advances Key Drug Candidates
TLDR
- Telomir Pharmaceuticals secures $3 million equity investment from The Bayshore Trust, offering a competitive advantage for strategic expansion.
- Telomir-1 and Telomir-Ag2 are cutting-edge drug candidates targeting age-reversal and drug-resistant infections respectively, with an IND submission planned by year-end.
- Telomir's innovative drug development aims to enhance longevity and quality of life for both humans and animals, contributing positively to healthcare advancements.
- Telomir Pharmaceuticals' commitment to shareholder-friendly financing with no warrants or toxic structures sets a new standard for ethical pharmaceutical investments.
Impact - Why it Matters
This news matters as Telomir Pharmaceuticals secures a significant equity investment, showcasing confidence in its drug development pipeline. The company's focus on age-reversal and combating drug-resistant infections could have far-reaching implications for the healthcare industry and potential investors.
Summary
Telomir Pharmaceuticals (NASDAQ: TELO) announced a $3 million equity investment from The Bayshore Trust, the company’s largest shareholder, through the purchase of 1 million restricted shares at $3.00 each—an 18% premium to the stock’s prior closing price. The raise brings total equity investment from affiliated entities to $4 million, complemented by an undrawn $5 million non-dilutive credit line. CEO Erez Aminov emphasized the company’s commitment to shareholder-friendly financing with no warrants or toxic structures. Telomir is advancing two key drug candidates: Telomir-1, a first-in-class age-reversal molecule with broad therapeutic potential, and Telomir-Ag2, a stabilized Silver(II) compound targeting drug-resistant infections. An IND submission for Telomir-1 is planned by year-end, with a focus on rare disease indications to demonstrate early efficacy.
To view the full press release, visit https://ibn.fm/yVVwy
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Telomir Pharmaceuticals Receives $3M Investment, Advances Key Drug Candidates
